SCHEMBL3813359

SCHEMBL3813359

CN(Cc1ccc(C(=O)N2CC3(C)CC2CC(C)(C)C3)cc1)C(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
ALDH1A1 P00352 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
AVPR1A P37288 12/20 0.51
AVPR2 P30518 8/20 0.51
HPGD P15428 1/20 0.48
HSD11B1 P28845 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3813805 0.93 LMNA (0.57) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL14532089 0.91 AVPR1A (0.58) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL3811241 0.91 AVPR1A (0.58) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL3814704 0.90 ALDH1A1 (0.55) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL14531718 0.90 LMNA (0.56) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL3813675 0.89 LMNA (0.55) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL4607419 0.86 ALDH1A1 (0.63) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL3814516 0.85 ALDH1A1 (0.52) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL14532032 0.85 ALDH1A1 (0.52) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL3811804 0.83 ALDH1A1 (0.66) LMNAALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US claimed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP claimed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO claimed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP disclosed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO disclosed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD11B2, HSD3B1 LMNA 3924/4885ALDH1A1 220/4885MEN1 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.